-
EP3681532
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3681532
| EP3681532 - PROTEINS BINDING NKG2D, CD16, AND C-TYPE LECTIN-LIKE MOLECULE-1 (CLL-1) [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 19.06.2020 Database last updated on 14.06.2024 | |
| Former | The international publication has been made Status updated on 22.03.2019 | Most recent event Tooltip | 27.04.2024 | Change - applicant | published on 29.05.2024 [2024/22] | Applicant(s) | For all designated states Dragonfly Therapeutics, Inc. 180 3rd Avenue, Sixth Floor Waltham, MA 02451 / US | [2024/22] |
| Former [2020/30] | For all designated states Dragonfly Therapeutics, Inc. 35 Gatehouse Drive Waltham, MA 02451 / US | Inventor(s) | 01 /
CHANG, Gregory, P. 143 Saunders Street Medford MA 02155 / US | 02 /
CHEUNG, Ann, F. 25 Morningside Lane Lincoln MA 01773 / US | 03 /
HANEY, William 61 Lincoln Road Wayland MA 01778 / US | 04 /
LUNDE, Bradley, M. 7 Lucent Drive Lebanon NH 03766 / US | 05 /
PRINZ, Bianka 7 Lucent Drive Lebanon NH 03766 / US | [2020/30] | Representative(s) | Redhouse, Juliet Lauren Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB | [N/P] |
| Former [2020/30] | Haseltine Lake Kempner LLP Lincoln House, 5th Floor 300 High Holborn London WC1V 7JH / GB | Application number, filing date | 18856132.8 | 13.09.2018 | [2020/30] | WO2018US50916 | Priority number, date | US201762558510P | 14.09.2017 Original published format: US 201762558510 P | [2020/30] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019055677 | Date: | 21.03.2019 | Language: | EN | [2019/12] | Type: | A1 Application with search report | No.: | EP3681532 | Date: | 22.07.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 21.03.2019 takes the place of the publication of the European patent application. | [2020/30] | Search report(s) | International search report - published on: | US | 21.03.2019 | (Supplementary) European search report - dispatched on: | EP | 03.08.2021 | Classification | IPC: | C07K16/28, C07K16/46 | [2021/35] | CPC: |
A61P35/00 (EP,EA,KR,US);
C07K16/2851 (EP,EA,KR,US);
A61K39/395 (EA);
C07K16/283 (EP,EA,KR,US);
A61K2039/505 (EP,EA,KR,US);
C07K2317/31 (US);
C07K2317/33 (EP,EA,KR,US);
C07K2317/524 (US);
C07K2317/565 (US);
C07K2317/569 (US);
C07K2317/73 (US);
C07K2317/75 (EP,EA,KR,US);
C07K2317/94 (EP,EA,KR,US)
(-)
|
| Former IPC [2020/30] | A61K39/00, A61K39/395, A61P35/00, C07K16/28, C07K16/46 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/30] | Extension states | BA | 15.06.2020 | ME | 15.06.2020 | Validation states | KH | 15.06.2020 | MA | 15.06.2020 | MD | 15.06.2020 | TN | 15.06.2020 | Title | German: | NKG2D, CD1 6 UND C-TYP-LECTIN-LIKE-MOLEKÜL 1 (CLL-1) BINDENDE PROTEINE | [2020/30] | English: | PROTEINS BINDING NKG2D, CD16, AND C-TYPE LECTIN-LIKE MOLECULE-1 (CLL-1) | [2020/30] | French: | PROTÉINES DE LIAISON À NKG2D, CD16, ET MOLÉCULE-1 SEMBLABLE À LA LECTINE DE TYPE C (CLL-1) | [2020/30] | Entry into regional phase | 20.03.2020 | National basic fee paid | 20.03.2020 | Search fee paid | 20.03.2020 | Designation fee(s) paid | 20.03.2020 | Examination fee paid | Examination procedure | 20.03.2020 | Examination requested [2020/30] | 28.02.2022 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 28.09.2020 | Renewal fee patent year 03 | 15.09.2021 | Renewal fee patent year 04 | 11.08.2022 | Renewal fee patent year 05 | 24.08.2023 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I]WO2007002905 (UNIV MIAMI [US], et al) [I] 1-16 * paragraphs [0012] , [0013] , [0060] , [0061] , [0065] , [0066] *; | [A]WO2009007124 (FRIEDRICH ALEXANDER UNI [DE], et al) [A] 1-16; | [A] - MAELIG G. MORVAN ET AL, "NK cells and cancer: you can teach innate cells new tricks", NATURE REVIEWS CANCER, London, (20160101), vol. 16, no. 1, doi:10.1038/nrc.2015.5, ISSN 1474-175X, pages 7 - 19, XP055484885 [A] 1-16 DOI: http://dx.doi.org/10.1038/nrc.2015.5 | [A] - GERMAIN CLAIRE ET AL, "MHC Class I-Related Chain a Conjugated to Antitumor antibodies Can Sensitize Tumor Cells to Specific Lysis by Natural Killer Cell", CLINICAL CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20051015), vol. 11, no. 20, doi:10.1158/1078-0432.CCR-05-0872, ISSN 1078-0432, pages 7516 - 7522, XP008084621 [A] 1-16 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-05-0872 | [A] - CHRISTIAN KELLNER ET AL, "Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype", ONCOIMMUNOLOGY, US, (20130627), vol. 2, no. 6, doi:10.4161/onci.24481, ISSN 2162-4011, page e24481, XP055684159 [A] 1-16 DOI: http://dx.doi.org/10.4161/onci.24481 | [A] - HARUKO TASHIRO ET AL, "Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1", MOLECULAR THERAPY, US, (20170901), vol. 25, no. 9, doi:10.1016/j.ymthe.2017.05.024, ISSN 1525-0016, pages 2202 - 2213, XP055579188 [A] 1-16 DOI: http://dx.doi.org/10.1016/j.ymthe.2017.05.024 | [A] - X. ZHAO ET AL, "Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia", HAEMATOLOGICA, (20090731), vol. 95, no. 1, doi:10.3324/haematol.2009.009811, ISSN 0390-6078, pages 71 - 78, XP055094666 [A] 1-16 DOI: http://dx.doi.org/10.3324/haematol.2009.009811 | [A] - ANNA VAN RHENEN ET AL, "The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 110, no. 7, doi:10.1182/BLOOD-2007-03-083048, ISSN 0006-4971, (20071001), pages 2659 - 2666, (20070703), XP002632479 [A] 1-16 DOI: http://dx.doi.org/10.1182/BLOOD-2007-03-083048 | [AP] - EDUARDO LABORDA ET AL, "Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia", INT. J. MOL. SCI., (20171101), vol. 18, no. 11, doi:10.3390/ijms18112259, ISSN 1661-6596, page 2259, XP055690425 [AP] 1-16 DOI: http://dx.doi.org/10.3390/ijms18112259 | International search | [A]US2010056764 (URSOE BIRGITTE [DK], et al) [A] 1-4, 20, 21* entire document *; | [A]US2011311535 (DRANOFF GLENN [US], et al) [A] 1-4, 20, 21 * entire document *; | [X]WO2017125897 (NOVARTIS AG [CH]) [X] 1-4, 20, 21 * entire document *; | [PX]WO2018157147 (DRAGONFLY THERAPEUTICS INC [US]) [PX] 1-4, 20, 21 * entire document * |